Case Studies, Pharmaceutical

Case Study – Unidose Nasal Spray Pump in Hypoglycemia

The conventional rescue medicine for hypoglycemia is an intramuscular injection of glucagon which must be reconstituted at point of use. This case study describes a collaborative drug repurposing project with Aptar Pharma culminating in the development of a glucagon nasal powder, an easier to administer alternative. The product utilizes Aptar Pharma’s patented Unidose Powder (UDS) device, is easy-to-store, and has a shelf-life of two years from manufacture. It provides diabetes patients with a highly effective rescue medicine that can be administered by a range of potential carers. Success rates with the nasal powder have been shown to exceed those with injectable glucagon and the product’s market value is expected to exceed $150 million by 2025.

Download Case Study - Unidose Nasal Spray pump in hypoglycemia
8 Sep 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More About nasal drug delivery expertise

This Might Also Be of Interest

6 Nov 2023

Nasal Inhalation Testing: IPAC-RS Droplet Size Analysis

Publications, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
13 Oct 2023

Nasal Drug Delivery: In Vitro Anatomical Models

Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
4 Aug 2023

Aptar Pharma Discusses Intranasal Drug Delivery with PharmTech

Podcasts, Pharmaceutical, Brand Differentiation, Market Insights, Product Solutions, Device Innovations

Read More
3 Jul 2023

Nasal Spray Orientation & Sumatriptan Exposure using PK Modelling

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
1 2 3 22

Request Access

Close

Requesting access to Case Study – Unidose Nasal Spray Pump in Hypoglycemia.

  • This field is for validation purposes and should be left unchanged.
Back To Top